Establishment of an efficient gene transfer system to normal epithelial cells and its application for cancer research

正常上皮细胞高效基因转移系统的建立及其在癌症研究中的应用

基本信息

  • 批准号:
    15590358
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

Determination of optimal condition for retroviral vector infection of normal epithelial cells.We found that culturing in Epilife medium (Cascade), serum free and low-calcium medium, under 3% Oxygen condition significantly improve the growth of normal human epithelial cells, and thereby the efficiency of infection with, retroviral vectors. Under this condition, we have achieved around 70-80% efficiency of infection. Using this condition, we first introduced ecotropic retrovirus receptor gene making human cells susceptible to ecotropic retrovirus whose host range is limited to rodent cells. This enabled us to introduce oncogenes using ecotropic retroviral vector into human epithelial cells, providing a good system in terms of biosafety. We succeeded in making such human epithelial cells expressing ecotropic receptor using epidermal keratinocytes, bronchial epithelial cells.Establishment of immortalized human epidermal keratinocytes.Using the system described above, we consecutively introduced hTERT(human catalytic subunit of telomerase), Cdk4, and dominant negative mutant of p53 in normal human epidermal keratinocytes. The resulting cells seemed to be immortalized but still retain normal function of differentiation in response to calcium and serum.Expression of dominant acting oncogenes in human epithelial cells.Next, we analyzed the effect of dominant acting oncogenes in these immortalized human epidermal keratinocytes. Expression of activated H-Ras mutant (H-Ras V12) resulted in the formation of many vacuolated cells which died subsequently. Expression of N-terminally truncated active mutant of b-catenin reduced the growth rate. Both of these oncogenes could not induce malignant transformation of the immortalized human epidermal keratinocytes.
确定逆转录病毒载体感染正常上皮细胞的最佳条件。我们发现在Epilife培养基(Cascade)、无血清低钙培养基、3%氧气条件下培养可显着提高正常人上皮细胞的生长,从而提高逆转录病毒载体的感染效率。在这种情况下,我们的感染效率达到了70-80%左右。利用这种条件,我们首先引入了亲嗜性逆转录病毒受体基因,使人类细胞对亲嗜性逆转录病毒敏感,其宿主范围仅限于啮齿动物细胞。这使得我们能够利用亲嗜性逆转录病毒载体将癌基因引入人类上皮细胞,在生物安全方面提供了良好的系统。我们成功地利用表皮角质形成细胞、支气管上皮细胞制作了表达共亲性受体的人类上皮细胞。建立了永生化的人类表皮角质形成细胞。使用上述系统,我们连续将hTERT(人类端粒酶催化亚基)、Cdk4和p53的显性失活突变体引入正常人体内 表皮角质形成细胞。所得细胞似乎是永生化的,但仍保留对钙和血清反应的正常分化功能。人上皮细胞中显性作用癌基因的表达。接下来,我们分析了这些永生化人表皮角质形成细胞中显性作用癌基因的作用。激活的 H-Ras 突变体 (H-Ras V12) 的表达导致许多空泡细胞的形成,这些细胞随后死亡。 N-末端截短的β-连环蛋白活性突变体的表达降低了生长速率。这两种癌基因均不能诱导永生化人表皮角质形成细胞的恶性转化。

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation
Human diploid fibroblasts are refractory to oncogene-mediated transformation
人二倍体成纤维细胞对癌基因介导的转化具有抵抗力
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Akagi;T.;Hanafusa;H.
  • 通讯作者:
    H.
Refractory nature of normal human diploid fibroblasts with respest to oncogene-mediated transformation
正常人二倍体成纤维细胞的难治性与癌基因介导转化的关系
Oncogenic transformation of human cells-shortcomings of roden model systems
人类细胞的致癌转化——啮齿动物模型系统的缺点
Akagi, T., Sasai, K., Hanafusa, H.: "Refrectory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation."Proc.Nati.Acad.Sci.USA. 100・23. 13567-13572 (2003)
Akagi, T.、Sasai, K.、Hanafusa, H.:“正常人二倍体成纤维细胞对癌基因介导的转化的抵抗性质。”Proc.Nati.Acad.Sci.USA 100・23。 2003)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AKAGI Tsuyoshi其他文献

AKAGI Tsuyoshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AKAGI Tsuyoshi', 18)}}的其他基金

A study on the mechanism of PI3K/AKT pathway activation by v-Crk oncogene
v-Crk癌基因激活PI3K/AKT通路机制的研究
  • 批准号:
    13670308
  • 财政年份:
    2001
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Identification of the cell type specific region for retroviral vector integration
逆转录病毒载体整合的细胞类型特异性区域的鉴定
  • 批准号:
    23701099
  • 财政年份:
    2011
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Influence of retroviral vector properties and processing parameters on retroviral transduction
逆转录病毒载体特性和加工参数对逆转录病毒转导的影响
  • 批准号:
    399979-2010
  • 财政年份:
    2010
  • 资助金额:
    $ 2.3万
  • 项目类别:
    University Undergraduate Student Research Awards
Quantitative and mechanistic analyses of retroviral vector transduction kinetics
逆转录病毒载体转导动力学的定量和机制分析
  • 批准号:
    353058-2007
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
    University Undergraduate Student Research Awards
Development of the new retroviral vector system for stem cell gene therapy.
开发用于干细胞基因治疗的新型逆转录病毒载体系统。
  • 批准号:
    18591180
  • 财政年份:
    2006
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Do retroviral vector insertions influence the fate of terminally differentiated cells such as T lymphocytes by insertional mutagenesis?
逆转录病毒载体插入是否会通过插入突变影响 T 淋巴细胞等终末分化细胞的命运?
  • 批准号:
    22728825
  • 财政年份:
    2006
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Priority Programmes
NGVL: RETROVIRAL VECTOR PRODUCTION FOR CLINICAL USE
NGVL:用于临床用途的逆转录病毒载体生产
  • 批准号:
    7389879
  • 财政年份:
    2005
  • 资助金额:
    $ 2.3万
  • 项目类别:
NGVL: RETROVIRAL VECTOR PRODUCTION FOR CLINICAL USE
NGVL:用于临床用途的逆转录病毒载体生产
  • 批准号:
    7166957
  • 财政年份:
    2005
  • 资助金额:
    $ 2.3万
  • 项目类别:
NGVL: RETROVIRAL VECTOR PRODUCTION FOR CLINICAL USE
NGVL:用于临床用途的逆转录病毒载体生产
  • 批准号:
    6982887
  • 财政年份:
    2004
  • 资助金额:
    $ 2.3万
  • 项目类别:
Retroviral vector for production of transgenic chickens
用于生产转基因鸡的逆转录病毒载体
  • 批准号:
    6739875
  • 财政年份:
    2004
  • 资助金额:
    $ 2.3万
  • 项目类别:
RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I
逆转录病毒载体介导的 MPS I 肝基因治疗
  • 批准号:
    8245107
  • 财政年份:
    2003
  • 资助金额:
    $ 2.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了